Analysis of Biomarkers From Patients With Chorioretinal Diseases

March 3, 2025 updated by: Dong Ho Park, Kyungpook National University Hospital
This study was conducted to investigate the levels of ocular biomarkers from the patients with chorioretinal diseases including diabetic retinopathy, retinal vascular diseases, age-related macular degeneration (dry and wet), and retinal degeneration.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

This prospective, case-control study included 50 patients(50eyes) with chorioretinal diseases including diabetic retinopathy, retinal vascular diseases, age-related macular degeneration (dry and wet), and retinal degeneration. and 50 patient with nondiabetic retinopathy or cataract. Ocular fluids and blood samples were taken before injection of anti-vascular endothelial growth factor agent or pars plana vitrectomy for other retinal disease. Ocular biomarkers were analyzed.

Study Type

Observational

Enrollment (Estimated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

A total of 100 patients will be included. 50 patients with chorioretinal diseases including diabetic retinopathy, retinal vascular diseases, age-related macular degeneration (dry and wet), and retinal degeneration. and 50 control patients scheduled for pars plana vitrectomy for nondiabetic retinal disease or phacoemulsification.

Description

Inclusion Criteria:

  • age over 20 years
  • patients requiring ophthalmologic treatments for different degrees of decreasing of visual acuity.
  • patients with chorioretinal diseases including diabetic retinopathy, retinal vascular diseases, age-related macular degeneration (dry and wet), and retinal degeneration.
  • control patients asking cataract surgery or vitrectomy for posterior segment nonproliferative disorders.

Exclusion Criteria:

  • under the age of 20 years
  • patients that received any anti-vascular endothelial growth factor agent for proliferative disease before taking sample of aqueous humor
  • patients that did not signed the informed consent of the trial
  • patients with intraocular inflammations or infections that requiring any pharmaceutical agent
  • patients with recent ocular trauma

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Chorioretinal diseases
chorioretinal diseases including diabetic retinopathy, retinal vascular diseases, age-related macular degeneration (dry and wet), and retinal degeneration.
Drug: Chorioretinal diseases
chorioretinal diseases including diabetic retinopathy, retinal vascular diseases, age-related macular degeneration (dry and wet), and retinal degeneration
Control
control patients with surgeries include pars plana vitrectomy of macular hole, epiretinal membrane, cataract surgery.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Biomarkers in ocular fluids
Time Frame: one month
To establish if certain type of chorioretinal diseases group are associated to different concentrations of gene or protein concentration.
one month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Kyungpook National University Hospital

Investigators

  • Principal Investigator: Dong Ho Park, M.D, Kyungpook National University Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2012

Primary Completion (Estimated)

February 1, 2028

Study Completion (Estimated)

April 1, 2031

Study Registration Dates

First Submitted

December 29, 2013

First Submitted That Met QC Criteria

December 31, 2013

First Posted (Estimated)

January 3, 2014

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

March 3, 2025

Last Verified

March 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • KNUH2013-1

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Macular Degeneration

Clinical Trials on Chorioretinal diseases

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovakia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe